Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Peptide Boom Puts Pressure on Synthesis
Drugs Already on the Market and in Clinical Studies Drive Novel Method Development
- Peptides are an emerging class of drugs, somewhere between a small molecule and a biologic. Their synthesis can be complex, which creates various challenges in large-scale production and purification. There are a number of companies involved in peptide manufacture and at least 150 peptide projects in the preclinical or ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.